APP and Alzheimer disease: Both genetic knockdown and pharmacological inhibition of ELK1 reduce APP amyloidogenic processing by promoting the SYVN1-mediated ubiquitination and degradation of PS1, thereby inhibiting Aβ generation and alleviating synaptic and cognitive impairments in a mouse model of AD.